Keith G Oldroyd

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6148379/publications.pdf

Version: 2024-02-01

234 papers	26,629 citations	13865 67 h-index	6131 159 g-index
239 all docs	239 docs citations	239 times ranked	14298 citing authors

#	Article	IF	Citations
1	Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size. Cardiovascular Research, 2022, 118, 1535-1547.	3.8	6
2	Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy. Platelets, 2022, 33, 141-146.	2.3	7
3	Fractional Flow Reserveâ€“Guided PCI as Compared with Coronary Bypass Surgery. New England Journal of Medicine, 2022, 386, 128-137.	27.0	169
4	A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI. International Journal of Cardiology, 2022, 347, 1-7.	1.7	3
5	A Noncontrast CMR Risk Score for Long-Term Risk Stratification in Reperfused ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Imaging, 2022, 15, 431-440.	5.3	8
6	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. JACC: Cardiovascular Interventions, 2022, 15, 282-293.	2.9	6
7	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drugâ€Eluting Stent Implantation: Perâ€Protocol Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association, 2022, 11, e024291.	3.7	4
8	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. EuroIntervention, 2022, 17, 1330-1339.	3.2	5
9	Quality of Life After Fractional Flow Reserveâ€“Guided PCI Compared With Coronary Bypass Surgery. Circulation, 2022, 145, 1655-1662.	1.6	6
10	Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial. EuroIntervention, 2022, 17, 1467-1476.	3.2	8
11	Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vsÂMultivessel PCI in Cardiogenic Shock Trial. Chest, 2021, 159, 1415-1425.	0.8	4
12	Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. Heart, 2021, 107, 299-312.	2.9	6
13	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. JACC: Cardiovascular Interventions, 2021, 14, 444-456.	2.9	27
14	Flow, pressure, anatomy: an eternal golden braid. Cardiovascular Research, 2021, 117, 1426-1427.	3.8	1
15	Thin Strut CoCr Biodegradable Polymer Biolimus A9-Eluting Stents versus Thicker Strut Stainless Steel Biodegradable Polymer Biolimus A9-Eluting Stents: Two-Year Clinical Outcomes. Journal of Interventional Cardiology, 2021, 2021, 1-7.	1.2	4
16	Safety and efficacy of Everolimusâ€Eluting bioabsorbable Polymerâ€Coated stent in patients with long coronary lesions: The EVOLVE 48 study. Catheterization and Cardiovascular Interventions, 2021, , .	1.7	2
17	Do we really understand how drug eluted from stents modulates arterial healing?. International Journal of Pharmaceutics, 2021, 601, 120575.	5.2	6
18	Distal Transradial (Snuffbox) Access for Coronary Catheterization: A Systematic Review. Cardiology in Review, 2021, 29, 210-216.	1.4	2

#	Article	IF	Citations
19	Thermodilution-derived temperature recovery time: a novel predictor of microvascular reperfusion and prognosis after myocardial infarction. EuroIntervention, 2021, 17, 220-228.	3.2	6
20	A novel algorithm for the computation of the diastolic pressure ratio in the invasive assessment of the functional significance of coronary artery disease. Panminerva Medica, 2021, 63, 206-213.	0.8	2
21	Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2021, 6, 1130.	6.1	114
22	Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR). European Heart Journal, 2021, 42, 4656-4668.	2.2	79
23	Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. JACC: Cardiovascular Interventions, 2021, 14, 1434-1446.	2.9	13
24	Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation, 2021, 144, 1476-1484.	1.6	121
25	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. European Heart Journal, 2021, 42, 4683-4693.	2.2	18
26	Comparison of risk prediction models in infarct-related cardiogenic shock. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 890-897.	1.0	11
27	Safety of Selective Intracoronary Hypothermia During Primary Percutaneous Coronary Intervention in Patients With Anterior STEMI. JACC: Cardiovascular Interventions, 2021, 14, 2047-2055.	2.9	15
28	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. European Heart Journal, 2021, 42, 4624-4634.	2.2	54
29	Risk Stratification Guided by the Index of Microcirculatory Resistance and Left Ventricular End-Diastolic Pressure in Acute Myocardial Infarction. Circulation: Cardiovascular Interventions, 2021, 14, e009529.	3.9	8
30	Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRITâ€SHOCK Substudy. Journal of the American Heart Association, 2021, 10, e021150.	3.7	1
31	Sex differences in procedural and clinical outcomes following rotational atherectomy. Catheterization and Cardiovascular Interventions, 2020, 95, 232-241.	1.7	24
32	1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA). JACC: Cardiovascular Interventions, 2020, 13, 33-45.	2.9	141
33	Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. Lancet, The, 2020, 395, 191-199.	13.7	280
34	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. Catheterization and Cardiovascular Interventions, 2020, 96, 1369-1378.	1.7	6
35	Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Function and CT Coronary Angiogram (CorCTCA) study. American Heart Journal, 2020, 221, 48-59.	2.7	27
36	Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 22-30.	3.0	7

#	Article	IF	Citations
37	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. European Heart Journal, 2020, 41, 3533-3545.	2.2	93
38	Economic evaluation of culprit lesion only PCI vs. immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: the CULPRIT-SHOCK trial. European Journal of Health Economics, 2020, 21, 1197-1209.	2.8	4
39	Redefining Adverse and Reverse Left Ventricular Remodeling by Cardiovascular Magnetic Resonance Following ST-Segmentâ€"Elevation Myocardial Infarction and Their Implications on Long-Term Prognosis. Circulation: Cardiovascular Imaging, 2020, 13, e009937.	2.6	24
40	Comparative Significance of Invasive Measures of Microvascular Injury in Acute Myocardial Infarction. Circulation: Cardiovascular Interventions, 2020, 13, e008505.	3.9	37
41	Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time. Journal of the American College of Cardiology, 2020, 75, 1406-1421.	2.8	16
42	A randomized controlled trial of a physiologyâ€guided percutaneous coronary intervention optimization strategy: Rationale and design of the TARGET FFR study. Clinical Cardiology, 2020, 43, 414-422.	1.8	13
43	One-Year Outcomes After Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008855.	3.9	5
44	Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction. European Heart Journal, 2020, 41, 3239-3252.	2.2	73
45	Effects of Intracoronary Alteplase on Microvascular Function in Acute Myocardial Infarction. Journal of the American Heart Association, 2020, 9, e014066.	3.7	11
46	Intravascular Imaging and 12-Month Mortality After Unprotected Left Main StemÂPCI. JACC: Cardiovascular Interventions, 2020, 13, 346-357.	2.9	70
47	Outcomes Associated with Respiratory Failure for Patients with Cardiogenic Shock and Acute Myocardial Infarction: A Substudy of the CULPRIT-SHOCK Trial. Journal of Clinical Medicine, 2020, 9, 860.	2.4	8
48	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2020, 75, 2403-2413.	2.8	60
49	Ticagrelor With or Without Aspirin After ComplexÂPCI. Journal of the American College of Cardiology, 2020, 75, 2414-2424.	2.8	122
50	Fractional Flow Reserveâ€"Based CoronaryÂArtery Bypass Surgery. JACC: Cardiovascular Interventions, 2020, 13, 1086-1096.	2.9	32
51	Percutaneous coronary intervention versus medical therapy in patients with angina and grey-zone fractional flow reserve values: a randomised clinical trial. Heart, 2020, 106, 758-764.	2.9	13
52	Evaluation and Management of Nonculprit Lesions in STEMI. JACC: Cardiovascular Interventions, 2020, 13, 1145-1154.	2.9	33
53	Continuous intracoronary versus standard intravenous infusion of adenosine for fractional flow reserve assessment: the HYPEREMIC trial. EuroIntervention, 2020, 16, 560-567.	3.2	4
54	Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-86.	0.7	0

#	Article	IF	Citations
55	Current Smoking and Prognosis AfterÂAcute ST-Segment Elevation MyocardialÂInfarction. JACC: Cardiovascular Imaging, 2019, 12, 993-1003.	5.3	46
56	Invasive Versus Medical Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary Syndrome. Circulation: Cardiovascular Interventions, 2019, 12, e007830.	3.9	17
57	Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet, The, 2019, 394, 1325-1334.	13.7	406
58	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. New England Journal of Medicine, 2019, 381, 2032-2042.	27.0	683
59	Predictors of segmental myocardial functional recovery in patients after an acute ST-Elevation myocardial infarction. European Journal of Radiology, 2019, 112, 121-129.	2.6	16
60	Predictive factors of discordance between the instantaneous waveâ€free ratio and fractional flow reserve. Catheterization and Cardiovascular Interventions, 2019, 94, 356-363.	1.7	49
61	Revascularisation and mechanical circulatory support in patients with ischaemic cardiogenic shock. Heart, 2019, 105, 1364-1374.	2.9	3
62	Sex-based associations with microvascular injury and outcomes after ST-segment elevation myocardial infarction. Open Heart, 2019, 6, e000979.	2.3	7
63	Prognostic Value and Risk Continuum of Noninvasive Fractional Flow Reserve Derived from Coronary CT Angiography. Radiology, 2019, 292, 343-351.	7.3	89
64	The Potential Use of the Index of Microcirculatory Resistance to Guide Stratification of Patients for Adjunctive Therapy in Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2019, 12, 951-966.	2.9	25
65	A protocol update of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 trial: A comparison of fractional flow reserveâ€"guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease. American Heart Journal, 2019, 214, 156-157.	2.7	10
66	Diastolic pressure ratio: new approach and validation vs. the instantaneous wave-free ratio. European Heart Journal, 2019, 40, 2585-2594.	2.2	44
67	Combining mathematical modelling with in vitro experiments to predict in vivo drug-eluting stent performance. Journal of Controlled Release, 2019, 303, 151-161.	9.9	28
68	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. International Journal of Cardiology, 2019, 286, 43-50.	1.7	19
69	50â€…Ischaemia and No Obstructive Coronary Artery Disease (INOCA): prevalence and predictors of coronary vasomotion disorders. , 2019, , .		0
70	Ischemia and No Obstructive Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2019, 12, e008126.	3.9	107
71	Circumferential Strain Predicts Major Adverse Cardiovascular Events Following an Acute ST-Segmentâ€"Elevation Myocardial Infarction. Radiology, 2019, 290, 329-337.	7.3	32
72	Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2019, 321, 56.	7.4	88

#	Article	IF	Citations
73	MINOCA: Requirement for Definitive Diagnostic Work-Up. Heart Lung and Circulation, 2019, 28, e4-e6.	0.4	3
74	Ischaemic Heart Disease. , 2019, , 355-363.		0
75	Intravascular ultrasound assessment of the effects of rotational atherectomy in calcified coronary artery lesions. International Journal of Cardiovascular Imaging, 2018, 34, 1365-1371.	1.5	17
76	Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. American Heart Journal, 2018, 201, 86-94.	2.7	22
77	Coronary microvascular dysfunction in patients with stable coronary artery disease: The CE-MARC 2 coronary physiology sub-study. International Journal of Cardiology, 2018, 266, 7-14.	1.7	41
78	Arterial Access for Invasive Coronary Angiography: The â€˜Left Backhanderâ€™. Heart Lung and Circulation, 2018, 27, e98-e99.	0.4	2
79	Persistent Iron Within the Infarct CoreÂAfter ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Imaging, 2018, 11, 1248-1256.	5.3	43
80	Rationale and design of the Coronary Microvascular Angina Cardiac Magnetic Resonance Imaging (CorCMR) diagnostic study: the CorMicA CMR sub-study. Open Heart, 2018, 5, e000924.	2.3	12
81	Access Site and Outcomes for Unprotected Left Main Stem Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 2480-2491.	2.9	12
82	Systemic microvascular dysfunction in microvascular and vasospastic angina. European Heart Journal, 2018, 39, 4086-4097.	2.2	139
83	Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina. Journal of the American College of Cardiology, 2018, 72, 2841-2855.	2.8	436
84	Coronary Thermodilution Waveforms After Acute Reperfused STâ€Segmentâ€“Elevation Myocardial Infarction: Relation to Microvascular Obstruction and Prognosis. Journal of the American Heart Association, 2018, 7, e008957.	3.7	5
85	Prognostic Value of the Residual SYNTAX Score After Functionally Complete Revascularization in ACS. Journal of the American College of Cardiology, 2018, 72, 1321-1329.	2.8	40
86	Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. New England Journal of Medicine, 2018, 379, 250-259.	27.0	622
87	Singleâ€•Versus 2â€•Stent Strategies for Coronary Bifurcation Lesions: A Systematic Review and Metaâ€Analysis of Randomized Trials With Longâ€Term Followâ€up. Journal of the American Heart Association, 2018, 7, .	3.7	53
88	Sex Differences in Adenosine-Free Coronary Pressure Indexes. JACC: Cardiovascular Interventions, 2018, 11, 1454-1463.	2.9	12
89	Hypertension, Microvascular Pathology, and Prognosis After an Acute Myocardial Infarction. Hypertension, 2018, 72, 720-730.	2.7	33
90	5â€…Effect of remote ischaemic preconditioning on coronary artery function in patients with stable coronary artery disease. , 2018, , .		0

#	Article	IF	Citations
91	1â€…Coronary microvascular dysfunction in stable coronary artery disease: the CE-MARC 2 coronary physiology sub-study. , 2018, , .		0
92	One-Year Outcomes after PCI Strategies in Cardiogenic Shock. New England Journal of Medicine, 2018, 379, 1699-1710.	27.0	303
93	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet, The, 2018, 392, 940-949.	13.7	555
94	Validation of a novel non-hyperaemic index of coronary artery stenosis severity: the Resting Full-cycle Ratio (VALIDATE RFR) study. EuroIntervention, 2018, 14, 806-814.	3.2	157
95	Culotte stenting for coronary bifurcation lesions with 2nd and 3rd generation everolimus-eluting stents: the CELTIC Bifurcation Study. EuroIntervention, 2018, 14, e318-e324.	3.2	16
96	Meta-Analysis of the Index of Microvascular Resistance in Acute STEMI Using Incomplete Data. JACC: Cardiovascular Interventions, 2017, 10, 421-422.	2.9	1
97	Validation of the â€œsmartâ€•minimum FFR Algorithm in an unselected all comer population of patients with intermediate coronary stenoses. International Journal of Cardiovascular Imaging, 2017, 33, 991-997.	1.5	3
98	Complete Immediate Revascularization of the Patient With ST-Segmentâ€“Elevation Myocardial Infarction Is the New Standard of Care. Circulation, 2017, 135, 1571-1573.	1.6	6
99	Time is still muscle and there is still room for improvement. Heart, 2017, 103, 96-97.	2.9	0
100	Is Delayed Stenting of the Culprit Artery in Patients With STEMI Ever Worth the Wait? â^—. Journal of the American College of Cardiology, 2017, 69, 2805-2807.	2.8	2
101	Diagnostic Accuracy of 3.0â€T Magnetic Resonance T1 and T2 Mapping and T2â€Weighted Darkâ€Blood Imaging for the Infarctâ€Related Coronary Artery in Nonâ€“STâ€Segment Elevation Myocardial Infarction. Journal of the American Heart Association, 2017, 6, .	3.7	15
102	Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicenter IDEAL-LM trial. American Heart Journal, 2017, 187, 104-111.	2.7	11
103	Comparison of Characteristics and Complications in Men Versus Women Undergoing Chronic Total Occlusion Percutaneous Intervention. American Journal of Cardiology, 2017, 119, 535-541.	1.6	35
104	PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. New England Journal of Medicine, 2017, 377, 2419-2432.	27.0	764
105	Meta-Analysis of Death and Myocardial Infarction in the DEFINE-FLAIR and iFR-SWEDEHEART Trials. Circulation, 2017, 136, 2389-2391.	1.6	32
106	Agreement of the Resting Distal toÂAorticÂCoronary Pressure With theÂInstantaneous Wave-Free Ratio. Journal of the American College of Cardiology, 2017, 70, 2105-2113.	2.8	43
107	Influence of Contrast Media Dose and Osmolality on the Diagnostic Performance of Contrast Fractional Flow Reserve. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	8
108	Protocol for an economic evaluation of the randomised controlled trial of culprit lesion only PCI versus immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: CULPRIT-SHOCK trial. BMJ Open, 2017, 7, e014849.	1.9	1

#	Article	IF	Citations
109	Safety and Efficacy of Polymer-Free Biolimus A9â€“Coated Versus Bare-Metal Stents in Orally Anticoagulated Patients. JACC: Cardiovascular Interventions, 2017, 10, 1633-1642.	2.9	11
110	Accuracy of Fractional Flow Reserve Measurements in Clinical Practice. JACC: Cardiovascular Interventions, 2017, 10, 1392-1401.	2.9	49
111	Persistence of Infarct Zone T2 Hyperintensity at 6 Months After Acute ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	16
112	Comparison of Different Diastolic RestingÂIndexes to iFR. Journal of the American College of Cardiology, 2017, 70, 3088-3096.	2.8	163
113	Radial Versus Femoral Access for Rotational Atherectomy. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	14
114	Infarct size and left ventricular remodelling after preventive percutaneous coronary intervention. Heart, 2016, 102, 1980-1987.	2.9	11
115	Remote Zone Extracellular Volume and Left Ventricular Remodeling in Survivors of ST-Elevation Myocardial Infarction. Hypertension, 2016, 68, 385-391.	2.7	44
116	Temporal Evolution of Myocardial Hemorrhage and Edema in Patients After Acute STâ€Segment Elevation Myocardial Infarction: Pathophysiological Insights and Clinical Implications. Journal of the American Heart Association, 2016, 5, .	3.7	96
117	â€œWaves of Edemaâ€•Seem Implausible. Journal of the American College of Cardiology, 2016, 67, 1868-1869.	2.8	5
118	Continuum of Vasodilator Stress FromÂRest to Contrast Medium toÂAdenosine Hyperemia for FractionalÂFlow Reserve Assessment. JACC: Cardiovascular Interventions, 2016, 9, 757-767.	2.9	129
119	Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. European Heart Journal, 2016, 37, 1923-1928.	2.2	103
120	Influence of access site choice for cardiac catheterization on risk of adverse neurological events: A systematic review and meta-analysis. American Heart Journal, 2016, 181, 107-119.	2.7	40
121	The EBC TWO Study (European Bifurcation Coronary TWO). Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	102
122	Discordance Between Resting and Hyperemic Indices of Coronary Stenosis Severity. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	67
123	The Influence of Lesion Location on the Diagnostic Accuracy of Adenosine-Free Coronary Pressure Wire Measurements. JACC: Cardiovascular Interventions, 2016, 9, 2390-2399.	2.9	81
124	Comparative Prognostic Utility of Indexes of Microvascular Function Alone or in Combination in Patients With an Acute ST-Segmentâ€“Elevation Myocardial Infarction. Circulation, 2016, 134, 1833-1847.	1.6	135
125	Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet, The, 2016, 388, 2743-2752.	13.7	620
126	115â€…Persistence of Infarct Zone Oedema at 6 Months after Acute ST-elevation Myocardial Infarction: Incidence, Pathophysiology and Association with Left Ventricular Remodelling. Heart, 2016, 102, A81.2-A81.	2.9	0

#	Article	IF	Citations
127	133â€…Although CT Coronary Angiography in the West of Scotland is Used in a Higher Risk Population than Recommended by Nice, The Rate of Subsequent Invasive Coronary Angiography is Lower than in the Promise and Scot-Heart Studies. Heart, 2016, 102, A95-A95.	2.9	0
128	114â€…Persistence of Haemoglobin Degradation Products within Infarct Scar Tissue after ST-elevation Myocardial Infarction: Incidence, Correlates and Implications for Left Ventricular Remodelling. Heart, 2016, 102, A81.1-A81.	2.9	0
129	2â€…Coronary flow reserve and index of microvascular resistance in acute stemi. Heart, 2016, 102, A1.2-A1.	2.9	0
130	The relationship between oxidised LDL, endothelial progenitor cells and coronary endothelial function in patients with CHD. Open Heart, 2016, 3, e000342.	2.3	12
131	Urine proteomics in the diagnosis of stable angina. BMC Cardiovascular Disorders, 2016, 16, 70.	1.7	20
132	Myocardial Hemorrhage After Acute Reperfused ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging, 2016, 9, e004148.	2.6	158
133	Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperfused ST-elevation myocardial infarction survivors. European Heart Journal, 2016, 37, 1044-1059.	2.2	105
134	Microvascular (Dys)Function and Clinical Outcome in Stable Coronary Disease. Journal of the American College of Cardiology, 2016, 67, 1170-1172.	2.8	27
135	Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. American Heart Journal, 2016, 172, 160-169.	2.7	93
136	Safety of guidewire-based measurement of fractional flow reserve and the index of microvascular resistance using intravenous adenosine in patients with acute or recent myocardial infarction. International Journal of Cardiology, 2016, 202, 305-310.	1.7	20
137	Microvascular resistance of the culprit coronary artery in acute ST-elevation myocardial infarction. JCI Insight, 2016, 1, e85768.	5.0	39
138	Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. Cost Effectiveness and Resource Allocation, 2015, 13, 19.	1.5	14
139	Impact of treatment algorithms on the prescribing of antithrombotic therapy in patients with suspected acute coronary syndrome â€“ a prospective audit. British Journal of Clinical Pharmacology, 2015, 80, 1176-1184.	2.4	0
140	Outcomes following implantation of the biolimus A9â€eluting Bio<scp>M</scp>atrix coronary stent: Primary analysis of the eâ€<scp>B</scp>io<scp>M</scp>atrix registry. Catheterization and Cardiovascular Interventions, 2015, 86, 1151-1160.	1.7	13
141	Physiological assessment of coronary lesion severity. Coronary Artery Disease, 2015, 26, e8-e14.	0.7	2
142	110â€…Infarct Burden Following Multivessel PCI Vs. Infarct-Only PCI in Patients with Acute Stemi: The Glasgow Prami CMR Sub-Study: Abstract 110 Table 1. Heart, 2015, 101, A63.1-A63.	2.9	0
143	Fractional flow reserve-guided management in stable coronary disease and acute myocardial infarction: recent developments. European Heart Journal, 2015, 36, 3155-3164.	2.2	58
144	Reducing In-Stent Restenosis. Journal of the American College of Cardiology, 2015, 65, 2314-2327.	2.8	95

#	Article	IF	Citations
145	Integrated Physiologic Assessment of Ischemic Heart Disease in Real-World Practice Using Index of Microcirculatory Resistance and Fractional Flow Reserve. Circulation: Cardiovascular Interventions, 2015, 8, e002857.	3.9	89
146	Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response. Thrombosis Research, 2015, 135, 1140-1146.	1.7	3
147	Invasive assessment of the coronary microcirculation in the catheter laboratory. International Journal of Cardiology, 2015, 199, 141-149.	1.7	12
148	Outcomes of Percutaneous Coronary Intervention Performed at Offsite VersusÂOnsite Surgical Centers inÂtheÂUnited Kingdom. Journal of the American College of Cardiology, 2015, 66, 363-372.	2.8	22
149	Pathophysiology of LV Remodeling inÂSurvivors of STEMI. JACC: Cardiovascular Imaging, 2015, 8, 779-789.	5.3	116
150	Repeatability of Fractional Flow Reserve Despite Variations in Systemic andÂCoronaryÂHemodynamics. JACC: Cardiovascular Interventions, 2015, 8, 1018-1027.	2.9	83
151	Current frontiers in the clinical research of coronary physiology. Interventional Cardiology, 2015, 7, 97-108.	0.0	0
152	Variation in thromboxane B2 concentrations in serum and plasma in patients taking regular aspirin before and after clopidogrel therapy. Platelets, 2015, 26, 17-24.	2.3	10
153	Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. New England Journal of Medicine, 2015, 373, 2038-2047.	27.0	672
154	Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: A comparison of fractional flow reserveâ€"guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease. American Heart Journal, 2015, 170, 619-626.e2.	2.7	58
155	Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial. Lancet, The, 2015, 386, 1853-1860.	13.7	455
156	Assessment of Fractional Flow Reserve in Patients With Recent Nonâ€"ST-Segmentâ€"Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2015, 8, e002207.	3.9	17
157	Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. European Heart Journal, 2015, 36, 100-111.	2.2	241
158	Five-year outcomes of staged percutaneous coronary intervention in the SYNTAX study. EuroIntervention, 2015, 10, 1402-1408.	3.2	9
159	Will this trial change my practice? TOTAL: a randomised trial of thrombus aspiration in ST-elevation myocardial infarction. EuroIntervention, 2015, 11, 361-363.	3.2	3
160	High-bolus dose tirofiban compared with abciximab in primary percutaneous coronary intervention: a propensity score-matched outcome study. EuroIntervention, 2015, 10, 1187-1194.	3.2	5
161	Is Hyperaemia Essential for Accurate Functional Assessment of Coronary Stenosis Severity?. Interventional Cardiology Review, 2015, 10, 72.	1.6	0
162	Does Routine Pressure Wire Assessment Influence Management Strategy at Coronary Angiography for Diagnosis of Chest Pain?. Circulation: Cardiovascular Interventions, 2014, 7, 248-255.	3.9	205

#	Article	IF	Citations
163	Impact of left ventricular function in relation to procedural outcomes following percutaneous coronary intervention: insights from the British Cardiovascular Intervention Society. European Heart Journal, 2014, 35, 3004-3012.	2.2	65
164	Response to Letter Regarding Article, â€œPrognostic Value of the Index of Microcirculatory Resistance Measured After Primary Percutaneous Coronary Interventionâ€• Circulation, 2014, 129, e342.	1.6	0
165	A Randomized Trial of Deferred Stenting Versus Immediate Stenting to Prevent No- or Slow-Reflow in Acute ST-Segment Elevation Myocardial Infarction (DEFER-STEMI). Journal of the American College of Cardiology, 2014, 63, 2088-2098.	2.8	204
166	Three-Year Results Comparing Platinum-Chromium PROMUS Element and Cobalt-Chromium XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Narrowing (from the PLATINUM Trial). American Journal of Cardiology, 2014, 113, 1117-1123.	1.6	37
167	Adenosine. JACC: Cardiovascular Interventions, 2014, 7, 581-591.	2.9	214
168	Multicenter Core Laboratory Comparison of the Instantaneous Wave-Free Ratio and Resting P /P With Fractional Flow Reserve. Journal of the American College of Cardiology, 2014, 63, 1253-1261.	2.8	301
169	Fractional flow reserve derived from coronary CT angiography: Variation of repeated analyses. Journal of Cardiovascular Computed Tomography, 2014, 8, 307-314.	1.3	45
170	Fractional Flow Reserveâ€“Guided PCI for Stable Coronary Artery Disease. New England Journal of Medicine, 2014, 371, 1208-1217.	27.0	905
171	Outcomes in Patients With ST-Segment Elevation Acute MyocardialÂInfarction Treated With Clopidogrel Versus Prasugrel (from the INFUSE-AMI Trial). American Journal of Cardiology, 2014, 113, 1457-1460.	1.6	35
172	Comprehensive Dobutamine Stress CMR Versus Echocardiography in LBBB and Suspected Coronary Artery Disease. JACC: Cardiovascular Imaging, 2014, 7, 490-498.	5.3	30
173	Fractional flow reserve and the index of microvascular resistance in patients with acute coronary syndromes. EuroIntervention, 2014, 10, T55-T63.	3.2	28
174	VERIFY (VERification of Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment) Tj ETQq0 0 0 rgBT /Overlock 10 Cardiology, 2013, 61, 1421-1427.	2.8	197
175	Randomized Trial of Preventive Angioplasty in Myocardial Infarction. New England Journal of Medicine, 2013, 369, 1115-1123.	27.0	871
176	Fractional flow reserve versus angiography in guiding management to optimize outcomes in nonâ€“ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial. American Heart Journal, 2013, 166, 662-668.e3.	2.7	11
177	The Impact of Coronary Bifurcation Stenting Strategy on Health-Related Functional Status. JACC: Cardiovascular Interventions, 2013, 6, 139-145.	2.9	8
178	The Role of Cardiac Magnetic Resonance Imaging (MRI) in Acute Myocardial Infarction (AMI). Heart Lung and Circulation, 2013, 22, 243-255.	0.4	31
179	Quality of life following percutaneous coronary interventions in octogenarians: a systematic review. Heart, 2013, 99, 779-784.	2.9	15
180	Usefulness of Fractional Flow Reserve to Improve Diagnostic Efficiency in Patients With Non-ST Elevation Myocardial Infarction. American Journal of Cardiology, 2013, 111, 45-50.	1.6	21

#	Article	IF	Citations
181	Vasodilatory Capacity of the Coronary Microcirculation is Preserved in Selected Patients With Nonâ€“ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2013, 6, 231-236.	3.9	103
182	Prognostic Value of the Index of Microcirculatory Resistance Measured After Primary Percutaneous Coronary Intervention. Circulation, 2013, 127, 2436-2441.	1.6	316
183	TRANSCATHETER AORTIC VALVE IMPLANTATION FOR SEVERE AORTIC STENOSIS: THE COST-EFFECTIVENESS CASE FOR INOPERABLE PATIENTS IN THE UNITED KINGDOM. International Journal of Technology Assessment in Health Care, 2013, 29, 12-19.	0.5	20
184	Succinobucolâ€eluting stents increase neointimal thickening and periâ€strut inflammation in a porcine coronary model. Catheterization and Cardiovascular Interventions, 2013, 81, 698-708.	1.7	12
185	TRANSCATHETER AORTIC VALVE IMPLANTATION FOR SEVERE AORTIC STENOSIS: THE COST-EFFECTIVENESS CASE FOR INOPERABLE PATIENTS IN THE UNITED KINGDOM â€“ CORRIGENDUM. International Journal of Technology Assessment in Health Care, 2013, 29, 112-112.	0.5	0
186	Microvascular Resistance Predicts Myocardial Salvage and Infarct Characteristics in STâ€Elevation Myocardial Infarction. Journal of the American Heart Association, 2012, 1, e002246.	3.7	80
187	Myocardial Repair and Regeneration: Bone Marrow or Cardiac Stem Cells?. Molecular Therapy, 2012, 20, 1102-1105.	8.2	15
188	Clinical outcomes following radial versus femoral artery access in primary or rescue percutaneous coronary intervention in Scotland: retrospective cohort study of 4534 patients. Heart, 2012, 98, 552-557.	2.9	45
189	CMR versus SPECT for diagnosis of coronary heart disease. Lancet, The, 2012, 379, 2145.	13.7	7
190	Fractional Flow Reserveâ€“Guided PCI versus Medical Therapy in Stable Coronary Disease. New England Journal of Medicine, 2012, 367, 991-1001.	27.0	2,248
191	The effect of reactive oxygen species on whole blood aggregation and the endothelial cell-platelet interaction in patients with coronary heart disease. Thrombosis Research, 2012, 130, 210-215.	1.7	25
192	Primary Endpoint Results of the EVOLVE Trial. Journal of the American College of Cardiology, 2012, 59, 1362-1370.	2.8	188
193	Instantaneous Wave-Free Ratio or Fractional Flow Reserve Without Hyperemia. Journal of the American College of Cardiology, 2012, 59, 1916-1917.	2.8	9
194	Prevention of coronary in-stent restenosis and vein graft failure: Does vascular gene therapy have a role?. , 2012, 136, 23-34.		25
195	Use of troponin to diagnose periprocedural myocardial infarction: effect on composite endpoints in the British Bifurcation Coronary Study (BBC ONE). Heart, 2012, 98, 1431-1435.	2.9	12
196	Simple or Complex Stenting for Bifurcation Coronary Lesions. Circulation: Cardiovascular Interventions, 2011, 4, 57-64.	3.9	152
197	Elective percutaneous coronary intervention in the elderly patient. Aging Health, 2011, 7, 271-281.	0.3	3
198	Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention. Biomarkers in Medicine, 2011, 5, 9-30.	1.4	3

#	Article	IF	Citations
199	Perioperative and long-term outcomes following aortic valve replacement: a population cohort study of 4124 consecutive patients. European Journal of Cardio-thoracic Surgery, 2011, 40, 1508-14.	1.4	10
200	Bright-Blood T2-Weighted MRI Has Higher Diagnostic Accuracy Than Dark-Blood Short Tau Inversion Recovery MRI for Detection of Acute Myocardial Infarction and for Assessment of the Ischemic Area at Risk and Myocardial Salvage. Circulation: Cardiovascular Imaging, 2011, 4, 210-219.	2.6	99
201	Low serum cortisol predicts early death after acute myocardial infarction. Critical Care Medicine, 2010, 38, 973-975.	0.9	24
202	The Index of Microcirculatory Resistance Measured Acutely Predicts the Extent and Severity of Myocardial Infarction in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2010, 3, 715-722.	2.9	161
203	Percutaneous Coronary Intervention in the Elderly. Circulation: Cardiovascular Interventions, 2010, 3, 341-345.	3.9	63
204	Randomized Trial of Simple Versus Complex Drug-Eluting Stenting for Bifurcation Lesions. Circulation, 2010, 121, 1235-1243.	1.6	478
205	Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention. European Heart Journal, 2010, 31, 222-226.	2.2	197
206	Randomized Comparison of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Diabetic Patients. Journal of the American College of Cardiology, 2010, 55, 432-440.	2.8	421
207	Angiographic Versus Functional Severity of Coronary Artery Stenoses in the FAME Study. Journal of the American College of Cardiology, 2010, 55, 2816-2821.	2.8	1,077
208	Fractional Flow Reserve Versus Angiography for Guiding Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery Disease. Journal of the American College of Cardiology, 2010, 56, 177-184.	2.8	990
209	Validation of Magnetic Resonance Myocardial Perfusion Imaging With Fractional Flow Reserve for the Detection of Significant Coronary Heart Disease. Circulation, 2009, 120, 2207-2213.	1.6	191
210	Radial versus femoral approach for highâ€speed rotational atherectomy. Catheterization and Cardiovascular Interventions, 2009, 74, 550-554.	1.7	53
211	Effect of clopidogrel discontinuation at 1Âyear after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug) Tj ETQq1 1 0.784314 rgBT /Overlo 410-417.	2.1	16
212	Drug-eluting stents: A study of international practice. American Heart Journal, 2009, 158, 576-584.	2.7	14
213	Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention. New England Journal of Medicine, 2009, 360, 213-224.	27.0	3,510
214	Three-year clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularisation Therapies Study, part II (ARTS II). EuroIntervention, 2009, 5, 190-196.	3.2	17
215	Pharmacological options for inducing maximal hyperaemia during studies of coronary physiology. Catheterization and Cardiovascular Interventions, 2008, 71, 198-204.	1.7	87
216	Validity of self-reported smoking status: Comparison of patients admitted to hospital with acute coronary syndrome and the general population. Nicotine and Tobacco Research, 2008, 10, 861-866.	2.6	45

#	Article	IF	Citations
217	Hospital and operator variations in drug-eluting stent use: a multi-level analysis of 5967 consecutive patients in Scotland. Journal of Public Health, 2008, 30, 186-193.	1.8	10
218	Smoke-free Legislation and Hospitalizations for Acute Coronary Syndrome. New England Journal of Medicine, 2008, 359, 482-491.	27.0	640
219	Drug-Eluting Stents Versus Bare-Metal Stents for Off-Label Indications. Circulation: Cardiovascular Interventions, 2008, 1, 45-52.	3.9	16
220	Drug-eluting stents: do the risks really outweigh the benefits?. Heart, 2008, 94, 127-128.	2.9	7
221	Bare-Metal versus Drug-Eluting Coronary Stents. New England Journal of Medicine, 2008, 358, 2516-2518.	27.0	4
222	Pro-healing drug-eluting stents: a role for antioxidants?. Clinical Science, 2008, 114, 265-273.	4.3	15
223	Importance of collateral circulation in coronary heart disease. European Heart Journal, 2007, 28, 278-291.	2.2	118
224	The clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularization Therapies Study part II (ARTS II). European Heart Journal, 2007, 28, 433-442.	2.2	113
225	The rise and fall of drug-eluting stents: Time trend analysis in 13647 consecutive patients undergoing percutaneous coronary intervention. American Heart Journal, 2007, 154, e37.	2.7	4
226	Rescue Angioplasty after Failed Thrombolytic Therapy for Acute Myocardial Infarction. New England Journal of Medicine, 2005, 353, 2758-2768.	27.0	436
227	Validation of coronary flow reserve measurements by thermodilution in clinical practice. European Heart Journal, 2004, 25, 219-223.	2.2	128
228	The RITA 3 trial. Lancet, The, 2002, 360, 1974.	13.7	2
229	A clinical and in vitro study on the possible interaction of intravenous nitrates with heparin anticoagulation. Clinical Cardiology, 1994, 17, 658-661.	1.8	7
230	Influence of hyperkalaemia and ischaemia on non-receptor-mediated cardiac electrophysiological effects of naloxone. Cardiovascular Research, 1993, 27, 296-303.	3.8	6
231	Pacing termination of spontaneous ventricular tachycardia in the coronary care unit. International Journal of Cardiology, 1992, 36, 223-226.	1.7	6
232	Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction. American Journal of Cardiology, 1991, 68, 713-718.	1.6	90
233	Free radical activity during percutaneous trans-luminal coronary angioplasty. Biochemical Society Transactions, 1990, 18, 1183-1184.	3.4	9
234	Dissecting aneurysm of a right-sided descending aorta with a left-sided aortic arch. International Journal of Cardiology, 1988, 18, 271-274.	1.7	2